Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Murcia – page 34

444 clinical trials in Murcia, Spain across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Murcia at a glance
444
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

444 trials in Murcia

Open in trial search

Colorectal cancer metastatic+1

Not recruiting

Study on Preventing Blood Clots with Tinzaparin in Patients with Metastatic Colorectal Cancer Starting First-Line Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Tinzaparin Sodium
  • Sponsor:Grupo Gallego De Investigacion En Tumores Digestivos

HIV infection

Not recruiting

Study on the Effectiveness and Safety of Lamivudine, Dolutegravir Sodium, Cabotegravir, and Rilpivirine for Adults with HIV-1 Who Have Not Taken Antiretroviral Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cabotegravir
  • Sponsor:Viiv Healthcare UK Limited

Myelofibrosis

Not recruiting

Study on the Effectiveness and Safety of Selinexor and Ruxolitinib for Patients with Myelofibrosis Who Have Not Received Prior Treatment

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:Karyopharm Therapeutics Inc.

Breast cancer

Not recruiting

Study of Trastuzumab Deruxtecan for Patients with Unresectable or Metastatic HER2-low or HER2 IHC0 Breast Cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Hypertrophic cardiomyopathy

Not recruiting

Study Comparing Aficamten and Metoprolol for Adults with Symptomatic Hypertrophic Cardiomyopathy

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Aficamten
  • Sponsor:Cytokinetics Inc.

Metastatic neoplasm

Not recruiting

Study on the Effects of Trastuzumab Deruxtecan in Patients with Advanced or Metastatic Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Solti Group

Gastroenteropancreatic neuroendocrine tumour disease

Not recruiting

Study on the Effectiveness and Safety of CAM2029 Compared to Octreotide and Lanreotide in Patients with Gastroenteropancreatic Neuroendocrine Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lanreotide
  • Sponsor:Camurus AB

Chronic myeloid leukaemia

Not recruiting

Study on Ponatinib for Patients with Chronic Myelogenous Leukemia in Molecular Response

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ponatinib
  • Sponsor:Fundacion Cris De Investigacion Para Vencer El Cancer

Follicular lymphoma+1

Not recruiting

Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Incyte Corp.

Malignant melanoma

Not recruiting

Study on Patient Preference for Nivolumab and Relatlimab Administration Methods in Melanoma Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Breast cancer+2

Not recruiting

Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:F. Hoffmann-La Roche AG

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study of Patritumab Deruxtecan with or without Endocrine Therapy for High-Risk HR+/HER2- Early Breast Cancer in Untreated Patients

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Patritumab Deruxtecan
  • Sponsor:Solti Group

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Murcia

What the registry says about research in the country

01 Oncology - Blood Cancers

Innovative clinical trials focusing on hematologic malignancies, including studies of new therapeutic combinations for chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. Research aims to evaluate novel treatment approaches and improve patient outcomes.

  • Chronic Myeloid Leukemia treatment optimization
  • Multiple Myeloma therapy combinations
  • Lymphoma management strategies
02 Solid Tumors

Comprehensive studies evaluating treatments for various solid tumors, including innovative approaches for breast cancer, melanoma, and gastric cancer. Research focuses on targeted therapies and immunotherapy combinations.

  • Advanced breast cancer treatments
  • Melanoma brain metastases therapy
  • Gastrointestinal cancer interventions
03 Neurological Conditions

Groundbreaking research in neurological disorders, particularly focusing on multiple sclerosis and acute cerebral ischemic stroke. Studies aim to evaluate new therapeutic agents and improve patient outcomes.

  • Stroke treatment innovations
  • Multiple sclerosis management
  • Neurological therapeutic advances
Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.